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Portal hypertension resulting from increased intrahepatic resis-
tance is a common complication of chronic liver diseases and a
leading cause of death in patients with liver cirrhosis, a scarring
process of the liver that includes components of both increased
fibrogenesis and wound contraction. A reduced production of
nitric oxide (NO) resulting from an impaired enzymatic function of
endothelial NO synthase and an increased contraction of hepatic
stellate cells (HSCs) have been demonstrated to contribute to high
intrahepatic resistance in the cirrhotic liver. 2-(Acetyloxy) benzoic
acid 3-(nitrooxymethyl) phenyl ester (NCX-1000) is a chemical
entity obtained by adding an NO-releasing moiety to ursodeoxy-
cholic acid (UDCA), a compound that is selectively metabolized by
hepatocytes. In this study we have examined the effect of NCX-
1000 and UDCA on liver fibrosis and portal hypertension induced
by i.p. injection of carbon tetrachloride in rats. Our results dem-
onstrated that although both treatments reduced liver collagen
deposition, NCX-1000, but not UDCA, prevented ascite formation
and reduced intrahepatic resistance in carbon tetrachloride-treated
rats as measured by assessing portal perfusion pressure. In contrast
to UDCA, NCX-1000 inhibited HSC contraction and exerted a
relaxing effect similar to the NO donor S-nitroso-N-acetylpenicil-
lamine. HSCs were able to metabolize NCX-1000 and release
nitriteynitrate in cell supernatants. In aggregate these data indi-
cate that NCX-1000, releasing NO into the liver microcirculation,
may provide a novel therapy for the treatment of patients with
portal hypertension.
Portal hypertension resulting from increased intrahepaticresistance is a common complication of chronic liver diseases
and a leading cause of death in patients with liver cirrhosis, a
scarring process of the liver that includes components of both
increased fibrogenesis and wound contraction (1). A close
relationship occurs between the progression of liver fibrosis and
development of portal hypertension. In particular, the develop-
ment of portal-central anastomosis and arterializationy
capillarization of liver sinusoids represents the hallmark of the
fibrogenic process as well as the key determinant for increased
intrahepatic vascular resistance (2). Portal-central anastomoses
are embedded in developing scar tissue where a complex inter-
play between several cell types and soluble mediators occurs.
Recent evidence links perisinusoidal hepatic stellate cells
(HSCs), also known as Ito cells or lipocytes, which are analogous
to tissue pericytes or vascular smooth muscle cells, to a role in
portal hypertension (3–5). Indeed, not only are HSCs involved
in collagen deposition and development of liver fibrosis, but they
also regulate intrahepatic blood flow by sinusoid contractiony
constriction (3–5). In the injured liver, HSCs undergo a striking
functional transition process termed activation. A critical feature
of the activation process is the acquisition of smooth muscle
isoforms of actin and myosin and enhanced contractile proper-
ties (5). The transitionyactivation process is associated with an
enhanced expression of receptors for endothelins, suggesting
that increases in intrahepatic resistance are, at least in part,
caused by an enhanced contractile response to these vasocon-
strictor agents (6, 7). HSC contraction is counterbalanced by
vasorelaxing agents such as nitric oxide (NO) (8). NO is an
ubiquitous messenger produced from conversion L-arginine to
L-citrulline by either constitutive or inducible NO synthase
(NOS) (9, 10). The constitutive NOS isoforms are localized
predominantly in neuronal cells and endothelial cells (eNOS) (9,
10). There is evidence that in the injured liver endothelin-1
production is increased (as a result of enhanced production by
HSCs) whereas NO release from sinusoidal endothelial cells is
reduced, ostensibly owing to impaired function of endothelial
cell eNOS (11–13). Because NO relaxes HSCs and antagonizes
the effect of endothelin-1, a reduced production of NO will
modify the dynamic balance of endothelin-1 and NO, favoring
sinusoidal and vascular wall constriction by perisinusoidal stel-
late cells and hepatic vascular smooth muscle cells (14–16).
Given the apparent defect of eNOS function in sinusoidal
endothelial cells of the cirrhotic liver, several pharmacological
approaches have been attempted to deliver NO directly to the
liver and reduce intrahepatic resistance (17–20). Nitrovadilators
have been the focus of current therapeutic approaches aimed at
intrahepatic vasodilation. Although these agents reduce portal
pressure in experimental animals and humans, recent studies
indicate that their systemic vasodilatory actions may have det-
rimental effects on portal hypertension patients, suggesting that
developing a compound(s) that selectively releases NO in the
liver without affecting systemic arterial pressure could repre-
sent a major advance in the treatment of this life-threatening
disease (21).
NO-releasing nonsteroidal anti-inflammatory drugs (NO-
NSAIDs) are a recently described class of NSAID derivatives
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generated by adding an NO-releasing moiety to parental
NSAIDs (22–24). NO-NSAIDs not only lack the gastrointestinal
damaging effect of classical NSAIDs, but the slow release of NO
in a biological microenvironment also confers novel activities not
shared by parent molecules (24). We and others have previously
demonstrated that, owing to their chemical structure, these
NO-NSAIDs release little amounts of NO in the systemic
circulation but transport NO to the liver where they are metab-
olized (24). Based on this background, we have hypothesized that
adding a NO-releasing moiety to ursodeoxycholic acid (UDCA),
a compound with an almost exclusive liver metabolism, would
have conferred to this new chemical entity the property of
selectively releasing significant amount of NO directly to the
liver and compensated for defective NO production in cirrhosis
(25). Indeed, in a previous study we have demonstrated that this
compound is metabolized in vitro by isolated hepatocytes to
release NO and NO-derived compounds and exerts potent
anti-apoptotic effects in animal models of liver injury (25).
The present study was designed to investigate whether NO-
UDCA, hereon referred to as NCX-1000 [2-(acetyloxy) benzoic
acid 3-(nitrooxymethyl) phenyl ester] (25) reduces portal hyper-
tension in an animal model of chronic liver injury and to define
the mechanism responsible for the protective effects. Our results
demonstrate that NCX-1000 prevents the development of portal
hypertension in cirrhotic rats by modulating HSC contractility.
Materials and Methods
Materials. Carbon tetrachloride (CCl4), UDCA, and urethane
were from Sigma, NCX-1000 was from Nicox (Milan, Italy), and
phenobarbital was from Bracco (Milan, Italy).
Induction of Cirrhosis. The study was approved by the Animal
Study Committee of the University of Perugia. Male Wistar rats
(150–180 g) were obtained from Charles River Breeding Lab-
oratories and maintained on standard laboratory rat chow on a
12-h lightydark cycle. They were given phenobarbital sodium (35
mgydl) with their drinking water for 3 days and then cirrhosis was
induced by i.p. injection of CCl4, 100 mly100 g body weight in an
equal volume of paraffin oil (21).
Study Protocol. Two parallel protocols were carried out. On the
first protocol, 54 rats, 12 animalsygroup unless specified, were
randomly allocated to receive one of the following treatments:
group 1 had phenobarbital induction and no further treatment;
group 2 (16 animals) was treated with CCl4 twice a week for 8
weeks; group 3 had CCl4 twice a week plus UDCA (15 mgykg);
and group 4 had CCl4 twice a week plus NCX-1000 (15 mgykg).
NCX-1000 and UDCA were dissolved in carboxymethyl cellu-
lose and administered daily by gavage. Animal weight was
monitored daily through the study period, and the dosage of CCl4
was adjusted accordingly to the animal weight. At the end of the
treatment surviving animals were killed by an overdose of
uretane, and blood, ascitic f luid, and livers were collected. A
portion of each liver was fixed in 10% formalin for histological
evaluation. The remaining tissue was partitioned and immedi-
ately stored under frozen liquid nitrogen at 280°C until used. On
the second protocol, 74 rats were randomly allocated to receive
the same treatments as protocol 1. At the end of the study,
surviving animals were tested for portal and arterial pressure
measurement (see below).
Liver Histology, Collagen Immunohistochemistry, and Biochemical
Assays. At least 2–3 liver samples (10–15 mgyeach) from each
animal were fixed in 10% formalin, embedded in paraffin,
sectioned, and stained with hematoxylin and eosin. For evalu-
ation of the liver type I collagen content, cryostat sections were
prepared from frozen liver, and immunohistochemistry was
carried out as described (28) by using a rabbit polyclonal
antibody against monkey pIp (procollagen type I N-terminal
propeptide), kindly donated by D. Schuppan, University of
Erlangen, Erlangen, Germany (16). The immunohistochemical
staining for collagen I was analyzed by a computerized video-
image analysis system, Leica (Cambridge) Quantiment
Q500MC. A total of five sections for each liver tissue sample
were observed under a light field microscope equipped with a
310 lens. The specific signal was acquired by a charge-coupled
device videocamera connected to the microscope. The signal was
converted to digital and transformed into pixel units. The
threshold of specific detection was automatically calibrated on
control sections stained with preimmune rabbit immunoglobu-
lins. Results were expressed as percent area occupied by the
signal. In each case, the area analyzed extended beyond the
central or portal vein into the surrounding lobule. The average
of the score taken from 10 random fields was used to generate
a single score for each animal’s liver. Liver function was assessed
by measuring plasma aspartate aminotransferase, bilirubin, al-
bumin, g-glutamyl transpeptidase, and alkaline fosfatase levels
by a 726 Hitachi (Tokyo) automatic analyzer as described (26).
Reverse Transcription–PCR Analysis of Liver eNOS and Aortic Inducible
NOS (iNOS). Total RNA was isolated from liver and thoracic aorta
by using TRIzol reagent (Life Technologies, Milan, Italy) as
described (25). Primers (Sigma) for rat eNOS were: 59-TTC
CGG CTG CCA CCT GAT CCT AA-39 (sense) and 59-AAC
ATG TGT CCT TGC TCG AGG CA-39 (antisense) and for
iNOS were: AAC AGT GGC AAC ATC AGG TCG G (sense)
and CTC CAA TCT CGG TGC CCA TGT A (antisense). The
b-actin primers were used as a control (25).
Liver eNOS Activity. Liver eNOS activity was assessed by deter-
mining the conversion of 3H-labeled L-arginine to 3H-labeled
L-citrulline based on a modified version of the method by Bredt
et al. (27). Briefly, liver tissue was homogenized in a lysis buffer
containing 0.1 mm EGTA, 50 mM TriszHCl, 0.1 mM EDTA, 5
mM leupeptin, 1 mM PMSF, 1% (volyvol) Nonidet P-40, 0.1%
SDS, and 0.1 mM deoxycholate at pH 7.5. Samples then were
incubated with a buffer containing 1 mM reduced nicotinamide
adenine dinucleotide phosphate, 3 mM tetrahydropterin, 11 nM
calmodulin, 2.5 mM CaCl2, 50 mM valine, 10 mM L-arginine, and
0.2 mCi of L-3H arginine at 37°C. To determine NOS activity,
samples were incubated for 20 min and the reaction was stopped
by adding 1 ml of cold stop buffer containing 20 mM Hepes, 2
mM EDTA, and 2 mM EGTA at pH 5.5. The mixture then was
passed over a Dowex AG 50WX-8X mesh cationic exchanging
resin column (Bio-Rad). The column was washed with an
additional 1 ml of the same solution, and L-3H citrulline was
collected and quantitated by liquid scintillation. Retrieved L-3H
citrulline was normalized to liver weight.
Liver NitriteyNitrate. Liver samples were homogenated (see
above), and nitriteynitrate concentrations were measured by a
fluorimetric detection kit (Cayman Chemicals, Ann Arbor, MI)
following the manufacturer’s instructions, as described. The
lower detection limit was ’4 pMywell.
Portal Pressure and Isolated Liver Perfusion. In vivo portal pressure
was measured in urethane anesthetized rats, control animals,
and cirrhotic animals, by cannulating the portal vein with a
polyethylene catheter (PE-50) and recorded with a strain-gauge
transducer connected with PowerLab PC (A.D. Instruments,
Milford, MA), according to a previously published method (13,
21). The bile duct was cannulated with polyethylene tubing
(PE-10). The hepatic artery was ligated. A ligature was passed
around the inferior vena cava above the renal veins, and the vein
was injected with 500 units of heparin. The portal vein then was
cannulated with a 16-gauge Teflon catheter. The liver was
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perfused immediately with Krebs solution containing 2 unitsyml
of heparin and oxygenated with carbogen gas (95% O2-5% CO2)
at 37°C. The inferior vena cava then was cut below the ligature,
thus allowing the perfusate to escape. Thereafter, the thorax was
opened and the supradiaphragmatic portion of the inferior vena
cava was cannulated with a 14-gauge Teflon catheter, and the
ligature around the vein was tied. The liver was perfused in a
nonrecirculating mode with Krebs solution equilibrated with
carbogen gas at variable rate (see Fig. 2) by using a peristaltic
pump (Gilson). The perfusion pressure was continuously mon-
itored and recorded with the strain-gauge transducer connected
to the portal inflow cannula ’10 cm proximal to the perfusion
cannula (13). Four rats for each group were tested for arterial
pressure measurement. Briefly, the left common carotid artery
was exposed through a cervical incision, and a 2FG polyethylene
cannula was introduced into the carotid artery via an arteriot-
omy. The cannula was connected to strain gauge transducer as
described before. After 25-min equilibration arterial and portal
pressure was recorded with the same apparatus.
HSC Contraction. HSCs were isolated from rat liver by the pro-
nase-collagenase method (28, 29). HSCs then were cultured on
uncoated plastic dishes where they spontaneously acquired an
activated phenotype, characterized by the expression of
a-smooth muscle actin and loss of vitamin A droplets. After
reaching confluency (about 14 days after plating), activated
HSCs were detached by incubation with trypsin (0.025% tryp-
siny0.5 mM EDTA), split in a 1:5 ratio, and subcultured as
described. Experiments were performed on cells between the
first and third serial passages. Contraction of HSCs on collagen
lattices was performed in 24-well f lat-bottom tissue culture
plates or 25-mm plastic culture dishes according to the method
described by Rockey et al. (29). Briefly, culture plates (Costar)
were preincubated with PBS containing 1% BSA (500 ml per
well) for at least 1 h at 37°C, then washed twice with PBS and
air-dried. A mixture of eight parts Vitrogen 100 (Nutacon,
Amsterdam, The Netherlands), 1 part 10 3 MEM, and 1 part 0.2
M Hepes (resulting in a final collagen concentration of 2.4
mgyml) was made at 4°C, added to the culture plates, and
incubated for 1 h at 37°C to allow gelation. HSCs were suspended
in a standard medium containing 20% FCS and layered on top
of formed lattice. Cell contraction then was induced by adding
FCS to the HSC monolayers (29). To assess whether NCX-1000
inhibited FCS-induced contraction, 100 mM NCX-1000, UDCA,
or S-nitroso-N-acetylpenicillamine (SNAP) were added to the
HSC monolayers, lactice then was detached by gentle circum-
ferential dislodgment with a 200-ml micropipet tip, and contrac-
tion was measured by monitoring the change in lattice area over
24 h. To assess whether NCX-1000 releases NO, HSCs were
incubated with UDCA, NCX-1000 or SNAP at 100 mM. At the
indicated time point (see Fig. 4) samples of supernatants were
collected and nitriteynitrate was measured by a fluorimetric
detection kit as described above. Intracellular NO formation in
NCX-1000-treated HSCs was carried out as described (25).
Briefly, HSCs cells (1 3 105yml) were loaded by suspending
them in PBS in the presence of 10 mM 4,5-diaminofluorescein
diacetate (Calbiochem). Cells were washed twice in iced buffer
solution, and samples were added to a quartz cuvette while
stirring continuously, and the temperature was thermostatically
maintained at 37°C by using a Hitachi 2000 fluorescence spec-
trophotometer. Samples were preincubated with 1 mM L-N6-
(1-iminoethyl) lysine for 30 min to suppress endogenous NO
generation and then incubated with 100 mM SNAP, NCX-1000,
or UDCA, and excited at 395 nm, and the intensity of fluores-
cence was emitted at 515 nm recorded. NO generation was
expressed in arbitrary units of absorbance.
Monocyte Chemotactic Protein-1 (MCP-1). HSC activation also was
assessed by measuring MCP-1 concentrations (R & D Systems)
in supernatants of HSCs (1 3 105yml) incubated with 100 ngyml
tumor necrosis factor a (TNF-a) and IFN-g for 24 h (30).
Statistical Analysis. ANOVA or Student’s t test were used for
statistical comparisons. For calculation of mean values and
statistical variation, n indicates the number of separate experi-
ments each with an individual cell preparation. Data are
means 6 SEM.
Results
NCX-1000 Prevents Ascite Formation in CCl4-Treated Rats. Long-term
CCl4 administration resulted in extensive liver damage and
nodular transformation. At laparotomy all CCl4-treated rats
showed macroscopically macroymicronodular cirrhosis of the
liver. The CCl4-treated animals had signs of portal hypertension
and splenomegaly increased diameter of the portal vein and its
intestinal afferents and ascites (Table 1). The weight of cirrhotic
rats was found to be significantly lower than that of sex- and
age-matched control animals (356.0 6 27.0 g vs. 463.0 6 18.0 g,
respectively; P , 0.0001) (Table 1). As shown in Table 1, treating
animals with UDCA or NCX-1000 had no effect on serum
albumin or bilirubin, although NCX-1000 caused a statistically
significant reduction of g-glutamyl transpeptidase. In contrast to
UDCA, NCX-1000 significantly reduced the percentage of an-
imals with ascites from 75% to 28.5% (P , 0.001) (Table 1). The
analysis of protein content in the ascitic f luid confirmed the
noninflammatory origin of the transudates. Moreover, in con-
trast to UDCA, NCX-1000 significantly decreased the amount of
nitriteynitrate content in the ascitic f luid (P , 0.01). Thus
NCX-1000, but not UDCA, reduces ascite formation in a rat
model of chronic liver injury.
NCX-1000 and UDCA Reduce Collagen Deposition. At immunohisto-
chemical analysis and semiquantitative scoring evaluation, liver
specimens obtained from rats treated with CCl4 showed exten-
sive central-portal, central-central, and portal-portal bridging
fibrosis (Fig. 1). In the CCl4-treated rats the total amount of type
I collagen was ’22.5% of total area (P , 0.01 versus controls).
UDCA and NCX-1000 decreased total liver collagen contents of
’50%, compared with the livers of animals treated with CCl4
Table 1. Effects of NO-UDCA and UDCA on body and liver weight, ascites, and liver-related serum parameters after 8 weeks of
CCl4-induced cirrhosis
Treatment (number of animals)
Body weight,
g
MAP,
mmHg
Albumin,
gydl
gGT,
unitsyliter
AST,
unitsyliter
Ascites,
%
Ascitic protein,
gyliter
Control (18) 463 6 18.2 120 6 4.1 4.4 6 0.8 38.7 6 27.7 50.5 6 19 0 0
CCl4 (20) 356 6 7.0 111 6 5.2 4.5 6 0.1 39.7 6 62.4 93 6 29 75 1.3 6 0.04
CCl4 1 UDCA (18) 356 6 3.4 114 6 2.8 3.9 6 0.4 27.4 6 17.9 153 6 52 62.5 1.2 6 0.1
CCl4 1 NO-UDCA (18) 386 6 22.0 116 6 3.1 4.3 6 0.2 8.8 6 6.6* 186 6 50 28.5* 1.2 6 0.1
Data are mean 6 SE. MAP, mean arterial pressure. AST, aspartate aminotransferase; gGT, g-glutamyl transpeptidase. *, P , 0.01 versus CCL4 alone.
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alone (P , 0.01); however, there were no rats with a histolog-
ically normal liver (Fig. 1).
NCX-1000 Reduces Portal Pressure in Cirrhotic Rats. Because these
data demonstrated that NCX-1000 and UDCA reduced liver
fibrosis, but UDCA had no effect on the percentage of animals
that developed ascites, we have reasoned that the NO-releasing
derivative should had protected against ascite development by
reducing portal pressure in cirrhotic rats. As shown in Fig. 2,
cirrhotic rats exhibited greater increases in perfusion pressure
than control rats in response to incremental increases in flow as
evidenced by a significantly greater perfusion pressure at each
flow rate (P , 0.01 in comparison with control rats; control, n 5
10; cirrhosis, n 5 7) (Fig. 2). NCX-1000 administration almost
completely reverted portal hypertension induced by CCl4 as
demonstrated by the fact that incremental increases in flow
failed to increase portal perfusion pressure (P , 0.001 in
comparison with CCl4 alone; NCX-1000, n 5 8). In contrast,
incremental increases in flow perfusion of portal vein of UDCA-
treated rats increased portal perfusion pressure to the same level
documented in rats treated with CCl4 alone (P . 0.05 in
comparison with CCl4 alone; UDCA, n 5 7). Thus, NCX-1000
significantly reduces intrahepatic resistance in cirrhotic rats as
measured by assessing portal perfusion pressure.
To gain insight on the mechanism through which NCX-1000
reduces portal pressure in cirrhotic rats, we measured eNOS
activity. Indeed, as shown in Fig. 3 A–C, although eNOS mRNA
expression was unchanged, eNOS activity was significantly re-
duced in cirrhotic rats in comparison with control rats. Treating
rats with NCX-1000 or UDCA had no effect on eNOS protein
expression or activity (Fig. 3C). However, liver nitriteynitrate
concentrations were significantly higher in rats treated with
NCX-1000 in comparison with animals treated with CCl4 alone
or CCl4 plus UDCA (Fig. 3C). In contrast NCX-1000 adminis-
tration markedly decreased nitriteynitrate contents in the ascitic
f luid (Fig. 3C). Because ascitic nitriteynitrate concentrations
reflect peripheral NO production, we then assessed eNOS and
iNOS expression in the aorta. In contrast to the liver, aortic
iNOS was significantly induced by CCl4 administration, an effect
that was completely reversed by cotreating the animals with
NCX-1000, but not with UDCA (Fig. 3D). No change were
measured on eNOS expression (data not shown).
NCX-1000 Modulates HSC Contraction. Having found that NCX-
1000 had no effect on eNOS activity but reduced portal hyper-
tension and increased liver NO content, we then assessed
whether NCX-1000 directly modulated HSC contraction. As
shown in Fig. 4A, NCX-1000 reverted HSC contraction induced
by FCS, indicating that HSCs are able to directly metabolize
NCX-1000. Indeed, as shown in Fig. 4 B and C, incubating HSC
with NCX-1000, 0.1 mM, resulted in time-dependent increase in
NO-related intracellular fluorescence in HSCs loaded with
4,5-diaminof luorescein diacetate, an NO-reactive f luoro-
crhome, as well as release of nitriteynitrate in cells supernatants.
Similarly to NCX-1000, the NO donor SNAP inhibited FCS-
induced contraction of HSCs and caused a time-dependent
formation of NO (Fig. 4 A–C). NCX-1000 also inhibited MCP-1
release from HSCs stimulated with TNF-a and IFN-g (Fig. 3D).
In contrast to NCX-1000, UDCA had no effect on HSCs
contraction, NO generation, and cytokine-induced MCP-1 re-
lease (Fig. 4).
Discussion
Clinical trials have demonstrated that the combination of
b-blockers and nitro-vasodilators is effective in reducing mor-
tality caused by gastrointestinal bleeding in patients with chronic
liver diseases. The rationale behind the use of these two drugs
is that by acting at separate points in the chain of pathophysi-
ologic events that lead to portal hypertension their combination
increases the portal pressure-lowering effect of either drug used
separately (17). A practical limitation of this approach, however,
derives from the fact that conventional NO donors, nitroglycerin
and isosorbide-5-mononitrate, release NO in the blood stream,
causing systemic hypotension and progression of the vasodila-
tory syndrome, aggravating renal dysfunction and sodium reten-
tion in cirrhotic patients with ascites (19, 20).
The increased intrahepatic vascular resistance in cirrhotic
patients is due not only to fixed anatomical changes inherent to
cirrhosis but also to active contraction of vascular smooth muscle
cells and, possibly, activated HSCs (3–6). This active contraction
is caused mainly by an impaired production of NO that acts in
Fig. 1. Liver collagen content in histological sections of rat liver
stained with anticollagen 1 antibody. Representative photomicro-
graphs of liver obtained from control (A) or cirrhotic rats. Rats were
treated for 8 weeks with CCl4 alone (B), CCl4 plus 15 mgykg per day
UDCA (C), or 15 mgykg per day NCX-1000 (D). In UDCA- and NCX-1000-
treated animals, lobular collagen is reduced. Collagen fibrils were
counted in 310 high-power fields per section. (E) Quantification of
liver collagen content. Values represent the mean 6 SEM of at least
eight rats. *, P , 0.01 versus control; **, P , 0.01 versus CCl4 alone.
Fig. 2. Flow-induced increases in perfusion pressure in control and cirrhotic
rats. The increase in perfusion pressure was greater in cirrhotic animals as
demonstrated by a significantly greater perfusion pressure at each flow rate.
*, P , 0.01 versus control and NCX-1000-treated rats.
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the liver as an endogenous vasodilator (2). In experimental
models of liver cirrhosis, as well as in cirrhotic patients, simul-
taneously with the excessive synthesis of NO in the systemic
vasculature there is an impaired enzymatic function of liver
eNOS despite the fixed expression of eNOS mRNA and protein
(11, 13). In endothelial cells eNOS catalytic activity is modulated
by dynamic regulatory processes including posttranslational pro-
tein modifications, interactions with regulatory proteins, and
availability of essential cofactors (13). It is well established that
the binding of eNOS with the ubiquitous calcium-regulatory
protein calmodulin promotes NO production, whereas caveo-
lin-1, the coat protein of nonclathrin-coated transport vesicles
and putative signaling molecule, decreases the catalytic activity
of the enzyme (31). Liver expression of calveolin-1 is increased
in cirrhotic rats, suggesting that an abnormal protein–protein
interaction is responsible for the defective eNOS function (13).
Moreover, because the cirrhotic liver is unable to respond to
incremental shear stress with an increased generation of NO, a
defect of mechanotransduction pathways responsible for flow-
mediated activation of eNOS also has been postulated (12, 13,
21). Whatever mechanism is responsible for presumed defect in
posttranslational handling of eNOS, transfecting cirrhotic rats
with a recombinant adenovirus carrying the neuronal NOS gene,
which undergoes lesser posttranslational modifications than
eNOS, leads to liver neuronal NOS overexpression and intra-
hepatic resistance reduction (21).
NCX-1000 is a NO-releasing derivative of UDCA generated
by adding a nitroxybutyl moiety to UDCA (25). We have
previously demonstrated that this compound, but not UDCA,
protects against liver damage induced by Con A in mice by
directly modulating liver resident immune system (25). Indeed in
comparison with currently available NO donors, NCX-1000 has
several potential advantages: (i) it is stable and releases NO very
slowly in the blood stream, a property that should minimize its
effect on arterial pressure, a major drawback of currently
available nitrates; and (ii) it is almost exclusively metabolized in
the liver, a property that should allow delivery of NO directly to
hepatic cells.
In the present study we have provided evidence that NCX-
1000 protects against development of portal hypertension in an
animal model of liver cirrhosis by reducing intrahepatic resis-
tance. Several of our results indeed support the concept that
NCX-1000 modulates both anatomical and dynamic component
of portal hypertension. First, UDCA and NCX-1000 exert
similar antifibrotic effects, but only NCX-1000 protects against
portal hypertension and ascite development induced by CCl4,
thereby demonstrating that NCX-1000 reverses the dynamic
component of portal hypertension, i.e., HSC contraction. Sec-
ond, similarly to UDCA, NCX-1000 has no effect on liver eNOS
expression and activity (Fig. 2), demonstrating that its effect is
unrelated to change in endogenous NO production. Third,
Fig. 3. (A) Reverse transcription–PCR analysis of liver eNOS expression. M,
molecular markers; 1, positive control; 2, negative control; lane 1, control
liver; lane 2, CCL4-treated rats; lane 3, UDCA-treated rats, and lane 4, NCX-
1000-treated rats. (B) eNOS activity (see Materials and Methods). Data are
mean 6 SEM of at least four determinations. *, P , 0.01 versus all other groups.
(C) Nitriteynitrate contents in liver extract and ascitic fluid. Data are mean 6
SEM of 4–8 determinations. *, P , 0.01 versus all other groups. (D) Reverse
transcription–PCR analysis of iNOS expression in homogenates obtained from
thoracic aortae. The lane markers are the same as in A.
Fig. 4. NCX-1000 inhibits HSC contraction. (A) HSC contraction induced by
FCS is inhibited by NCX-1000 and SNAP. Cells were incubated with 100 mM of
NCX-1000, UDCA, or SNAP, and contraction was induced by FCS (see Materials
and Methods). P , 0.01 versus control (FCS-treated cells) or UDCA-treated
cells. (B and C) Incubating HSCs with NCX-1000 and SNAP but not UDCA (100
mM) increases nitriteynitrate in cell supernatants (B) and intracellular NO-
related fluorescence (C). (D) NCX-1000, but not UDCA (100 mM), inhibits MCP-1
release from activated HSCs. *, P , 0.01 versus control; **, P , 0.01 versus cell
incubated with TNF-a plus IFN-g.
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NCX-1000 administration significantly increases liver content of
nitriteynitrate, demonstrating that liver cells are able to use
NCX-1000 as a source of NO despite a defect in posttranslational
handling of eNOS. Fourth, as a further index of its ability to
protect against development of portal hypertension, NCX-1000
reduces the nitriteynitrate content in the ascitic f luid and
prevents iNOS expression induction in the thoracic aorta, sug-
gesting that similar to other compounds generated with the same
technology (i.e., NO-NSAIDs), the NO-UDCA derivative mod-
ulates iNOS expression (32). Fifth, NCX-1000 has no effect on
mean arterial pressure, both in control and cirrhotic rats, indi-
cating that it releases a low amount of NO in the blood stream
(33). Sixth, NCX-1000 directly modulates HSC functions as
demonstrated by our in vitro experiments. Indeed NCX-1000
reduces HSC contraction as well as MCP-1 release induced by
TNF-a and IFN-g (30). The finding that SNAP also inhibits HSC
contraction (31) and that both compounds increase nitritey
nitrate release in cell supernatants as well as intracellular
fluorescence in cells loaded with the NO-reactive fluorochrome
4,5-diaminofluorescein diacetate, whereas UDCA itself has no
effect, strongly supports the view that NCX-1000 inhibits HSC
functions through an NO-dependent mechanism (25).
The results of the present study are important for another
reason, which is the demonstration that HSCs are able to directly
metabolize NCX-1000 to generate NO. This result is relevant
because hematogenous compounds must traverse the sinusoidal
endothelium as well as the sinusoidal space of Disse (wherein
reside stellate cells) before coming into contact with hepato-
cytes, making it possible for NCX-1000 to directly reach HSCs
from the perisinusoidal space (i.e., independently of hepatocyte
handling). If this is the case it cannot be excluded that hepatic
sinusoidal cells can use NCX-1000 as a source of NO.
In summary, the results presented in this study are consistent
with previous data indicating that nitrogenous compounds are
capable of affecting portal vascular resistance. Moreover, it
establishes that whatever mechanism is responsible for presumed
eNOS dysfunction it is possible to restore normal intrahepatic
resistance by a compound that selectively releases NO in the
liver. Finally, our data demonstrated that UDCA can be used as
a carrier to transport other biologically active molecules to the
liver with minimal systemic effects.
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